Tech Company Financing Transactions
Trevi Therapeutics Funding Round
On 6/4/2014, Trevi Therapeutics announced $25 million in Series B investment from TPG Biotech and private investors.
Transaction Overview
Company Name
Announced On
6/4/2014
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series B
Investors
TPG Biotech (Lead Investor) (Eran Nadav)
Proceeds Purpose
The Company plans to use the funding for the initiation of pivotal trials in two severe itch conditions: uremic pruritus and prurigo nodularis. The Company recently released data from its successfully completed Phase 1 trial in which Nalbuphine ER was shown to be well tolerated in patients on hemodialysis with itch and established proof-of-concept in uremic pruritus. The Company intends to initiate both pivotal trials in the third quarter of this year, and expects to have top-line results in the second half of 2015.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
195 Church St. 14th Floor
New Haven, CT 06510
USA
New Haven, CT 06510
USA
Phone
Website
Email Address
Overview
Trevi Therapeutics, Inc. is a drug development company founded in 2011 focused on developing T111 for the severe chronic itching condition known as pruritus. Pruritus is manifested in various dermatological, metabolic, hematologic and neuronal conditions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jennifer Good
Chief Financial Officer
Christopher Seiter
Chief Medical Officer
Thomas Sciascia
Vice President
Amale Hawi
VP - Bus. Development
Helena Brett-Smith
VP - Bus. Development
Yann Mazabraud
Browse more venture capital transactions:
Prev: 6/4/2014: Urban Remedy venture capital transaction
Next: 6/4/2014: PerBlue venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs